New ultrasound score may sharpen risk prediction for PAH patients
NCT ID NCT07266012
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed study looked at whether a new ultrasound score called VExUS can help doctors better assess risk in people with pulmonary arterial hypertension (PAH). Researchers measured VExUS in 86 adults and compared it to standard tests like heart catheterization and blood markers. The goal was to see if VExUS could spot early signs of fluid buildup and improve current risk models.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a better, non-invasive way to assess risk and congestion in PAH patients, potentially improving monitoring and treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial. The VExUS score may not prove useful enough to change current practice, and results may not apply to all PAH patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istanbul University-Cerrahpasa Institute of Cardiology
Istanbul, FATIH, 34098, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaled therapy replace a daily pill for PAH?
- Can a Real-World registry improve how treprostinil is used for PAH?
- Which PAH treatment strategy works better: adding a third drug or increasing the dose?
- Lung patients may soon do rehab from home via app
- Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
- New PAH drug IKT-001 moves to Long-Term safety check